Analyst Price Target is GBX 210
▲ +296.23% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Celadon Pharmaceuticals in the last 3 months. The average price target is GBX 210, with a high forecast of GBX 210 and a low forecast of GBX 210. The average price target represents a 296.23% upside from the last price of GBX 53.
Current Consensus is
The current consensus among 1 contributing investment analysts is to buy stock in Celadon Pharmaceuticals.
Celadon Pharmaceuticals Plc, a pharmaceutical company, engages in the research, manufacture, and supply of cannabinoids for use in approved medicines. The company focuses on growing indoor hydroponic THC cannabis for use in medicinal products used to treat chronic pain. It also intends to conduct research into cannabinoids for use in chronic pain, as well as other conditions, such as autism and multiple sclerosis. The company was founded in 2018 and is headquartered in London, the United Kingdom.